Cargando…
A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser
BACKGROUND: The Sysmex CN‐6500 is a new haemostasis analyser with an integrated immunoassay module that performs chemiluminescence enzyme assay (CLEIA) in addition to coagulation, turbidimetric, chromogenic and platelet aggregation tests. AIMS: To evaluate the analytical performance of the CN‐6500 a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292606/ https://www.ncbi.nlm.nih.gov/pubmed/34252265 http://dx.doi.org/10.1111/ijlh.13656 |
_version_ | 1784749411954327552 |
---|---|
author | Gardiner, Chris Lane, Philip Tailor, Hitesh Machin, Samuel J. Mackie, Ian J. |
author_facet | Gardiner, Chris Lane, Philip Tailor, Hitesh Machin, Samuel J. Mackie, Ian J. |
author_sort | Gardiner, Chris |
collection | PubMed |
description | BACKGROUND: The Sysmex CN‐6500 is a new haemostasis analyser with an integrated immunoassay module that performs chemiluminescence enzyme assay (CLEIA) in addition to coagulation, turbidimetric, chromogenic and platelet aggregation tests. AIMS: To evaluate the analytical performance of the CN‐6500 against the predicate device (Sysmex HISCL‐800) for soluble thrombomodulin (TM), thrombin‐antithrombin (TAT), tissue plasminogen activator/plasminogen activator inhibitor 1 complex (tPAI‐C) and plasmin α2 plasmin inhibitor complex (PIC) assays. METHODS: Imprecision was assessed by testing two levels of quality control plasmas 10 times on 5 separate days. Comparability was studied in 230 plasmas from normal donors (n = 30), patients with suspected disseminated intravascular coagulation (DIC, n = 100), sepsis (n = 20) or liver disease (n = 20), lipaemic (n = 20), haemolysed (n = 20) and icteric samples (n = 20). Limit of detection, limit of quantitation and linearity were determined by testing serial dilutions of normal plasma. Sample carryover was assessed by testing samples with high and low normal levels of the analytes concerned. RESULTS: The CN‐6500 performed 21 CLEIA tests per hour, while simultaneously performing coagulation tests. Acceptable between‐run imprecision was obtained using commercial controls with normal and high activity for each analyte (%CV <4%), for all four assays. Excellent linearity was observed (slope 0.89‐1.03; r(2) >0.99) across the measurement range. The lower limits of detection and quantitation were as follows: TM <0.3/0.6 TU/ml, TAT >0.1/<0.2 ng/ml, PIC <0.004/<0.008 µg/ml and tPAI‐C < 0.01/<0.1 ng/ml, respectively. All four assays showed excellent correlation between analysers and were unaffected by haemolysis, icterus or lipaemia. No carryover was observed. CONCLUSIONS: Our data demonstrate that the performance of the CLEIA assays on the CN‐6500 is comparable to that of a stand‐alone immunoassay analyser. |
format | Online Article Text |
id | pubmed-9292606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92926062022-07-20 A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser Gardiner, Chris Lane, Philip Tailor, Hitesh Machin, Samuel J. Mackie, Ian J. Int J Lab Hematol ORIGINAL ARTICLES BACKGROUND: The Sysmex CN‐6500 is a new haemostasis analyser with an integrated immunoassay module that performs chemiluminescence enzyme assay (CLEIA) in addition to coagulation, turbidimetric, chromogenic and platelet aggregation tests. AIMS: To evaluate the analytical performance of the CN‐6500 against the predicate device (Sysmex HISCL‐800) for soluble thrombomodulin (TM), thrombin‐antithrombin (TAT), tissue plasminogen activator/plasminogen activator inhibitor 1 complex (tPAI‐C) and plasmin α2 plasmin inhibitor complex (PIC) assays. METHODS: Imprecision was assessed by testing two levels of quality control plasmas 10 times on 5 separate days. Comparability was studied in 230 plasmas from normal donors (n = 30), patients with suspected disseminated intravascular coagulation (DIC, n = 100), sepsis (n = 20) or liver disease (n = 20), lipaemic (n = 20), haemolysed (n = 20) and icteric samples (n = 20). Limit of detection, limit of quantitation and linearity were determined by testing serial dilutions of normal plasma. Sample carryover was assessed by testing samples with high and low normal levels of the analytes concerned. RESULTS: The CN‐6500 performed 21 CLEIA tests per hour, while simultaneously performing coagulation tests. Acceptable between‐run imprecision was obtained using commercial controls with normal and high activity for each analyte (%CV <4%), for all four assays. Excellent linearity was observed (slope 0.89‐1.03; r(2) >0.99) across the measurement range. The lower limits of detection and quantitation were as follows: TM <0.3/0.6 TU/ml, TAT >0.1/<0.2 ng/ml, PIC <0.004/<0.008 µg/ml and tPAI‐C < 0.01/<0.1 ng/ml, respectively. All four assays showed excellent correlation between analysers and were unaffected by haemolysis, icterus or lipaemia. No carryover was observed. CONCLUSIONS: Our data demonstrate that the performance of the CLEIA assays on the CN‐6500 is comparable to that of a stand‐alone immunoassay analyser. John Wiley and Sons Inc. 2021-07-12 2021-12 /pmc/articles/PMC9292606/ /pubmed/34252265 http://dx.doi.org/10.1111/ijlh.13656 Text en © 2021 The Authors. International Journal of Laboratory Hematology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | ORIGINAL ARTICLES Gardiner, Chris Lane, Philip Tailor, Hitesh Machin, Samuel J. Mackie, Ian J. A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser |
title | A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser |
title_full | A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser |
title_fullStr | A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser |
title_full_unstemmed | A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser |
title_short | A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser |
title_sort | performance evaluation of chemiluminescence enzyme immunoassays on the sysmex cn‐6500 haemostasis analyser |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292606/ https://www.ncbi.nlm.nih.gov/pubmed/34252265 http://dx.doi.org/10.1111/ijlh.13656 |
work_keys_str_mv | AT gardinerchris aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser AT lanephilip aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser AT tailorhitesh aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser AT machinsamuelj aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser AT mackieianj aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser AT gardinerchris performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser AT lanephilip performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser AT tailorhitesh performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser AT machinsamuelj performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser AT mackieianj performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser |